Drug Design and Discovery in Alzheimer’s Disease


Atta-ur-Rahman, Mohammad Iqbal Choudhary

DOI: 10.2174/97816080582281150101
eISBN: 978-1-60805-822-8, 2014
ISBN: 978-1-60805-823-5
ISSN: 1574-0889 (Print)
ISSN: 2212-1064 (Online)

Indexed in: Book Citation Index, Science Edition, BIOSIS Previews, Scopus, EMBASE, EBSCO, Ulrich's Periodicals Directory.

“Frontiers in Drug Design and Discovery” is an Ebook series devoted to publishing the latest and the most important advances in drug d...[view complete introduction]
US $
Buy Personal eBook
Order Library eBook
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

Neprilysin Inhibitors Provide Insight into its Specificity and Therapeutic Potential

- Pp. 598-622 (25)

Darrick Pope and Michael Cascio


Neprilysin (NEP) is one of the enzymes in the zinc-metalloendopeptidase family that displays a broad specificity in degrading small bioactive peptides. Crystal structures of seven NEP-inhibitor complexes as well as biochemical characterization of NEP activity have highlighted amino acid interactions that are crucial to the binding of various ligands. Studies also indicate that NEP is one of a select group of metalloenzymes that degrade the amyloid beta peptide (Aβ) in vivo and in situ. The accumulation of neurotoxic Aβ aggregates in the brain appears to be a causative agent in the pathophysiology of Alzheimer’s Disease (AD). For this reason the enzymatic degradation of Aβ has been studied extensively, but little is currently known about the specific interactions underlying NEP degradation of Aβ. Research that pertains to these interactions may lead to critical insights for utilizing NEP inhibition of Aβ accumulation as a safe, beneficial AD therapy.

Purchase Chapter  Book Details


Webmaster Contact: info@benthamscience.net Copyright © 2019 Bentham Science